Benefício da Iodoterapia no Câncer de Tireoide com extensão e metástase no pescoço

Benefit of Adjuvant Therapy with I131 in patients with Differentiated Thyroid Carcinoma with minimal extrathyroidal extension and after re-operation for persistent or recurrent lymph node metastases

Status

Recruiting

Phases

Phase 3

Study type

Interventional

Source

REBEC

Registry ID

RBR-7fy9gss

Enrollment

Unknown

Registered

2025-12-08

Start date

2017-01-01

Completion date

Unknown

Last updated

2026-01-12

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Thyroid Cancer, Papillary

Interventions

This is an open-label, randomized, controlled clinical trial with four arms. Patients with differentiated thyroid carcinoma will be recruited and divided into two groups: one with minimal extrathyroid

Eligibility

Age

18 Years to No maximum

Inclusion criteria

Inclusion criteria: Patients with Differentiated thyroid carcinoma; minimal extrathyroidal extension; reoperation for persistent or recurrent lymph node metastases; aged over 18 years

Exclusion criteria

Exclusion criteria: Known distant metastases; distant metastasis diagnosed on whole-body scan with diagnostic I131

Design outcomes

Primary

Measure	Time frame
To assess recurrence-free survival at 1, 2, and 5-year follow-up	—

Secondary

Measure	Time frame
Evaluate the response to treatment at 1, 2, and 5 years	—

Countries

Brazil

Contacts

Public ContactCaroline Oliveira

Fundação Faculdade de Medicina

endocrinocaroline@gmail.com+55(11)2661-7176

Outcome results

None listed

Source: REBEC (via WHO ICTRP)